All filters
Slidesets
State of the ART: What’s the same – what’s different – Is it clinicially relevant?- Eric Arts, PhD
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
Monitoring and avoiding integrase inhibitor toxicity- Gordon Arbess, MD, CCFP
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
Reducing HIV associated inflammation – do the drugs matter?- Darrell Tan, BSc, MD, FRCPC, PhD
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
Improving care of HIV infected women: What needs to be done?- Sharon Walmsley, FRCPC, MD, MSC
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
Reduced drug regimens – Pros and Cons- Gary Rubin, MD
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
Novel drug delivery systems: will they have a place in routine HIV clinical care? (Not yet available)- Courtney Fletcher, PharmD
Presented at:
Canadian HIV Clinical Forum 2018
Slidesets
What is the Virological support for reduced drug regimens?- Josep Llibre, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
State of the ART: Integrase Inhibitors Clinical Data- Juan Berenguer, MD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study- Jésus Troya
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Interstitial pneumonia by triple viral co-infection in a CDC C2 HIV- infected patient- Carme Bracke
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Clinical Case presentation- Antonio Antela, MD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Integrating novel delivery systems/novel drugs- Maria Luisa Montes, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
What is the Pharmacological support for reduced drug regimens?- Esteban Ribera, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
HIV integrase Inhibitors: A novel mechanisms of action- Dr. H. Wu
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Abstract-driven presentation: Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Treatment-Naïve Asian Adults: Week 144 results- Tina Zheng
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Abstract-driven presentation: Efficacy and Safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in Virologically Suppressed Asian Adults with Renal Impairment: 144 Week- Ning Li
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Taiwan’s Experiences with Integrase Inhibitors- Chien-Ching Hung, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Long-term HIV treatment: The Importance of Initial Antiretroviral Regimen Selection- Hongxin Zhao, MD, MPH
Presented at:
Chinese HIV Clinical Forum 2018